Skip to main content

Are peptides a solution for the treatment of hyperactivated JAK3 pathways?

Abstract

While the inactivation mutations that eliminate JAK3 function lead to the immunological disorders such as severe combined immunodeficiency, activation mutations, causing constitutive JAK3 signaling, are known to trigger various types of cancer or are responsible for autoimmune diseases, such as rheumatoid arthritis, psoriasis, or inflammatory bowel diseases. Treatment of hyperactivated JAK3 is still an obstacle, due to different sensibility of mutation types to conventional drugs and unwanted side effects, because these drugs are not absolutely specific for JAK3, thus inhibiting other members of the JAK family, too. Lack of information, in which way sole inhibition of JAK3 is necessary for elimination of the disease, calls for the development of isoform-specific JAK3 inhibitors. Beside this strategy, up to date peptides are a rising alternative as chemo- or immunotherapeutics, but still sparsely represented in drug development and clinical trials. Beyond a possible direct inhibition function, crossing the cancer cell membrane and interfering in disease-causing pathways or triggering apoptosis, peptides could be used in future as adjunct remedies to potentialize traditional therapy and preserve non-affected cells. To discuss such feasible topics, this review deals with the knowledge about the structure–function of JAK3 and the actual state-of-the-art of isoform-specific inhibitor development, as well as the function of currently approved drugs or those currently being tested in clinical trials. Furthermore, several strategies for the application of peptide-based drugs for cancer therapy and the physicochemical and structural relations to peptide efficacy are discussed, and an overview of peptide sequences, which were qualified for clinical trials, is given.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

Sources: Elliott et al. (2011), Degryse et al. (2014), Sato et al. (2008), Kiyoi et al. (2007), Stein et al. (2018), Bouchekioua et al. (2014), Bellanger et al. (2014), Zhang et al. (2018), Losdyck et al. (2015), Springuel et al. (2014), Assi et al. (2017), Sic et al. (2017), Forster et al. (2016), Yamashita et al. (2010), Riera et al. (2011), Bergmann et al. (2014)

Fig. 3

Source: Buchert et al. (2016)

References

Download references

Acknowledgements

We would like to acknowledge the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for scholarships. We would also like to thank the University of Vale do Taquari-UNIVATES and the Secretaria do Desenvolvimento Econômico, Ciência e Tecnologia do Rio Grande do Sul (SDECT) for financial support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Márcia Inês Goettert.

Ethics declarations

Conflict of interest

The author(s) did not declare any conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dullius, A., Rocha, C.M., Laufer, S. et al. Are peptides a solution for the treatment of hyperactivated JAK3 pathways?. Inflammopharmacol 27, 433–452 (2019). https://doi.org/10.1007/s10787-019-00589-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-019-00589-2

Keywords

  • JAK3 inhibition
  • Kinase isoform selectivity
  • Activation mutations
  • Anticancer peptides
  • Peptide-based adjunct drugs
  • Immunotherapeutics